CITIC International has raised the target price for HENLIUS to RMB 61.98, expecting significant potential in innovative drug development

AASTOCKS
2025.06.25 03:13

Zhao Yin International published a research report stating that HENLIUS (02696.HK) has the capability to develop from a profitable biosimilar company into a leading enterprise in the biopharmaceutical field. Several innovative drugs under development, including HLX43, HLX22, and Serplulimab, have shown good clinical data performance. The report believes in the company's substantial growth potential, thus raising the target price from HKD 20.33 to HKD 61.98, maintaining a "Buy" rating.

Zhao Yin International believes that HENLIUS is actively expanding its global biosimilar business through collaborations with pharmaceutical companies. Its products "Hanquyou" (Trastuzumab) and Serplulimab have shown strong commercialization performance, while the marketing authorization applications for HLX14 and HLX11 are currently under FDA review, which is expected to open up overseas revenue sources

Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.